Displaying 2681 - 2700 of 4770
1503003 Informal Interpretation
1502004 Informal Interpretation
FTC Puts Conditions on Novartis AG’s Proposed Acquisition of GlaxoSmithKline’s Oncology Drugs
Boehringer Ingelheim Pharmaceuticals, Inc.
Zillow, Inc. and Trulia, Inc.
Statement of Commissioner Ohlhausen, Commissioner Wright, and Commissioner McSweeny Concerning Zillow, Inc/Trulia, Inc
FTC Challenges Proposed Merger of Sysco and US Foods
FTC, DOJ Announce Agenda for Joint Public Workshop on Examining U.S. Health Care Competition
1502003 Informal Interpretation
FTC Approves Merck & Co., Inc.’s Application to Sell Facilities for Manufacturing Heartgard and Heartgard Plus Heartworm Treatments for Dogs to Merial
Schering-Plough Corporation, , In the Matter of
The Commission challenged Schering-Plough’s proposed $41.4 billion acquisition of Merck & Co., and required divestitures to preserve competition in markets for human and animal pharmaceuticals. The proposed consent order requires that Merck sell its interest in Merial Limited, an animal health joint venture with Sanofi-Aventis S.A., and that Schering-Plough sell its assets related to significant drugs for nausea and vomiting in humans.
Statement by FTC Chairwoman Edith Ramirez on Appellate Ruling in the St. Luke’s Hospital Matter
1502002 Informal Interpretation
FTC Submits Fiscal Year 2016 Budget Request, Performance Plan, and Fiscal Year 2014 Performance Report to Congress
Announcement of Second Public Workshop on Examining Health Care Competition
1501004 Informal Interpretation
1501005 Informal Interpretation
FTC Puts Conditions on Sun Pharmaceutical’s Proposed Acquisition of Ranbaxy
Displaying 2681 - 2700 of 4770